Compugen Q1 2026 Results and Clinical Pipeline Update

Compugen reported its first quarter 2026 financial results and provided updates on its clinical pipeline. The company's COM701 MAIA-ovarian trial for platinum-sensitive ovarian cancer is actively enrolling patients across U.S., Israel, and France sites, with an interim analysis on track for Q1 2027. Partner AstraZeneca is advancing rilvegostomig across 11 ongoing Phase 3 trials, with new data to be presented at ASCO 2026. Gilead-partnered GS-0321 Phase 1 trial continues to progress as planned. Financially, Compugen reported $134.9 million in cash and equivalents as of March 31, 2026, with cash runway expected to fund operations into 2029. Q1 2026 revenues were $2.2 million, with a net loss of $7.7 million ($0.08 per share). R&D expenses increased to $6.9 million primarily due to clinical trial costs for the MAIA-ovarian study.